Here is how Caribou Biosciences, Inc. (CRBU) and Bioventus (BVS) have performed compared to their se

BERKELEY, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a lead

-- Single dose of CB-011 produced deep, durable responses in heavily pretreated, BCMA-naïve patients

-- Single dose of vispa-cel produced durable responses in 2L LBCL patients: 82% ORR, 67% CR rate, an

-- Single dose of CB-011 produced deep, durable responses in heavily pretreated, BCMA-naïve patients

Caribou Biosciences NASDAQ: CRBU Chief Executive Officer Rachel Haurwitz said the company is advanci

Caribou Biosciences, Inc. (CRBU) Presents at Jefferies Global Healthcare Conference 2026 Transcript

BERKELEY, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leadi

Caribou Biosciences, Inc. (CRBU) Presents at Bank of America Global Healthcare Conference 2026 Trans

BERKELEY, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leadi

Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceu

BERKELEY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leadi

HC Wainwright & Co. analyst Robert Burns maintains Caribou Biosciences (NASDAQ:CRBU) with a B

Caribou Biosciences, Inc. (CRBU) came out with a quarterly loss of $0.26 per share versus the Zacks

Caribou Biosciences (NASDAQ:CRBU) reported quarterly losses of $(0.26) per share which beat the anal

-- Achieved alignment with FDA on pivotal ANTLER-3 trial design for vispa-cel in 2L LBCL -- -- Longe

BERKELEY, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leadi

Genomics gains momentum as breakthroughs, falling sequencing costs, and CRISPR advances drive precis

HC Wainwright & Co. analyst Robert Burns reiterates Caribou Biosciences (NASDAQ:CRBU) with a

Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmace

-- RMAT granted based on promising initial clinical data, including previously disclosed recommended

Caribou Biosciences offers the strongest allogeneic CAR-T data to date, with efficacy and safety riv

Executives from Caribou Biosciences (NASDAQ: CRBU) outlined upcoming clinical, regulatory, and finan

Evercore ISI Group analyst Jonathan Miller maintains Caribou Biosciences (NASDAQ:CRBU) with a Out

Caribou Biosciences, Inc. (CRBU) came out with a quarterly loss of $0.28 per share versus the Zacks

Caribou Biosciences (NASDAQ:CRBU) reported quarterly losses of $(0.28) per share which beat the anal

BERKELEY, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a lea

Clear Street analyst Bill Maughan initiates coverage on Caribou Biosciences (NASDAQ:CRBU) with a

Caribou Biosciences (NASDAQ:CRBU) reported quarterly losses of $(0.30) per share which beat the anal

HC Wainwright & Co. analyst Robert Burns maintains Caribou Biosciences (NASDAQ:CRBU) with a B

  Friday's session saw 104 companies set new 52-week lows.

  On Monday, 198 companies hit new 52-week lows.

Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday.

  During Monday's trading, 1214 companies set new 52-week lows.

  During Thursday, 849 stocks hit new 52-week lows.

  Wednesday's session saw 784 companies set new 52-week lows.

  On Tuesday, 242 companies hit new 52-week lows.

  During Tuesday's session, 454 stocks hit new 52-week lows.

    On Friday, 368 stocks hit new 52-week lows.

    During Wednesday's morning trading, 400 companies set new 52-week lows.

  During Friday's session, 445 companies made new 52-week lows.